GEORGE V MIGAUSKY
CIK 1134365 · EVP & Chief Financial Officer · last filed 2026-06-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.79M
Companies
7
Total Filings
49
Lifetime Open-Market Net
-$3.54M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RGNX | Director | 28,861 | $11.28 | $325.6K | $0 | 6 | 2026-06-02 |
| IMVT | Director | 137,251 | $39.74 | $5.45M | -$451.0K | 8 | 2025-04-03 |
| ABEO | Director | 1,518 | $6.90 | $10.5K | $0 | 1 | 2020-06-19 |
| Immunovant, Inc. (IMVTW) Delisted | Director | 44,700 | — | — | $0 | 1 | 2020-05-18 |
| Dimension Therapeutics, Inc. (DMTX) Delisted | Director | — | — | — | $0 | 3 | 2017-11-07 |
| DYAX CORP (DYAX) Delisted | EVP & Chief Financial Officer | 0 | — | — | -$3.08M | 25 | 2016-01-22 |
| BIOVERIS CORP (BIOV) Delisted | Chief Financial Officer | 136,335 | — | — | $0 | 1 | 2007-01-09 |
Recent Filings · Page 2 of 5
49 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-04-14 | IMVT | Grant (A) | +12,523 | $0 | EDGAR |
| 2022-08-19 | IMVT | Grant (A) | +21,059 | $0 | EDGAR |
| 2022-06-07 | RGNX | Grant (A) | +3,010 | $0 | EDGAR |
| 2022-01-12 | IMVT | Grant (A) | +21,726 | $0 | EDGAR |
| 2021-09-08 | RGNX | Grant (A) | — | $0 | EDGAR |
| 2021-08-20 | IMVT | Buy (P) | +7,000 | $53.5K | EDGAR |
| 2021-03-23 | IMVT | Grant (A) | +15,500 | $0 | EDGAR |
| 2020-06-19 | ABEO | Grant (A) | +37,954 | $0 | EDGAR |
| 2020-05-18 | Immunovant, Inc. (IMVTW) Delisted | Grant (A) | +24,700 | $0 | EDGAR |
| 2017-11-07 | Dimension Therapeutics, Inc. (DMTX) Delisted | Disp (D) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.